Alessandro Battaggia

Dr. Alessandro Battaggia

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAlessandro Battaggia
Alessandro Battaggia
ADAlberto Donzelli
Alberto Donzelli
MFMaria Font
Maria Font
DMDavide Molteni
Davide Molteni
Antonio GalvanoAntonio Galvano
Antonio Galvano
Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same dosage, with a follow-up at least 24 weeks and one or more of these outcomes: all-cause mortality, cardiovascular (CV) mortality, stroke, myocardial infarction (MI), cancer, serious adverse events (SAEs); we assessed the risk of bias using the Cochrane checklist. We extracted the data for major clinical events as a dichotomous measure, with the patient the unit of analysis. Pooled analysis was done with random and fixed effect based models. Trials comparing Ezetimibe plus a lipid-lowering drug against the same lipidlowering drug representing the net effect of Ezetimibe, showed a nonsignificant tendency toward damage for cancer, MI, stroke and SAEs. Ezetimibe+simvastatin vs. simvastatin alone showed a stronger tendency towards a higher risk for all-cause death (2.52; 0.65-9.74), CV death (3.04; 0.48-19.21), non-CV death (3.03; 0.12-73.50), MI (1.91; 0.42-8.70), stroke (2.38; 0.46-12.35), cancer (RR 11.11; 0.62-198.29), and SAEs (1.45; 0.95-2.23). Limitations include small numbers of events and inadequate power of the pooling. Trials comparing Ezetimibe+simvastatin vs placebo showed non-significant effects: MI (0.81; 0.66-1.00 p = 0.051), all-cause death (1.02; 0.95-1.09), CV death (0.91; 0.80-1.04), non-CV death (108; 0.99-1.18), stroke (0.86; 0.72-1.04), cancer (1.18; 0.80-1.74), SAEs (1.01; 0.96-1.06). Ezetimibe±simvastatin had inconsistent effects on important outcomes. No firm conclusions are possible, but findings indicative of damage suggest much more selective use of Ezetimibe±simvastatin.

26 February 2009 in Journal of Human Hypertension
Verified
Journal Article
Closed access
AFA Filippi
A Filippi
IPI Paolini
I Paolini
FIF Innocenti
F Innocenti
GMG Mazzaglia
G Mazzaglia
ABAlessandro Battaggia
Alessandro Battaggia
OBO Brignoli
O Brignoli

24 September 2012 in European Journal of General Practice
Verified
Journal Article
Closed access
PDF file
MCMaurizio Cancian
Maurizio Cancian
ABAlessandro Battaggia
Alessandro Battaggia
MCMario Celebrano
Mario Celebrano
FZFrancesco Del Zotti
Francesco Del Zotti
BNBruno Franco Novelletto
Bruno Franco Novelletto
RTRoberto Toffanin
Roberto Toffanin
Background: In Italian primary care, chronic heart failure (CHF) patients are mainly managed by general practitioners (GPs). However, there are few studies analysing CHF management challenges in primary care and identifying opportunities for improvement. Objectives: To describe CHF care as implemented by GPs in the Veneto Region and to identify opportunities for improvement. Methods: In 2008, using an audit process, 114 Venetian GPs analysed their electronic health records, identified CHF patients and collected clinical and care related information: prevalence, co-morbidity, caring conditions, diagnostic and therapeutic management, and hospitalization. After two training sessions, data on pharmacotherapy were analysed again in 2009. Results: The prevalence of CHF was 1.2% (95% CI: 1.1–1.3%). Diagnostic echocardiography was used in 57% of cases. At baseline, the proportions of patients that used specific medication were: diuretics 88%; angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) 77%, beta-blockers 46% and anti-aldosterone agents 32%. After two training sessions, the use of ACE inhibitors/ARB and beta-blockers increased to 80% and 56%, respectively. Renal failure, chronic obstructive pulmonary disease (COPD), diabetes mellitus and dementia were the most prevalent concomitant diseases, posing specific management problems. Half of the patients were generally visited at home; they were dependent on some kind of care given. Conclusion: In Veneto a large number of CHF patients are mainly managed by GPs. Further improvements are necessary to meet standards of care with regard to diagnosis, medication, follow-up and home care. The care situation affected hospitalization and the quality of follow-up visits.

16 September 2017 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
ABAlessandro Battaggia
Alessandro Battaggia
ASAndrea Scalisi
Andrea Scalisi
LPLuca Puccetti
Luca Puccetti

1 September 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ABAlessandro Battaggia
Alessandro Battaggia
PAPierangelo Lora Aprile
Pierangelo Lora Aprile
ICIacopo Cricelli
Iacopo Cricelli
DFDiego Maria Michele Fornasari
Diego Maria Michele Fornasari
AFAndrea Fanelli
Andrea Fanelli
FLFrancesco Lapi
Francesco Lapi

1 January 2019 in Journal of Drug Assessment
Verified
Journal Article
Open access
ABAlessandro Battaggia
Alessandro Battaggia
ASAndrea Scalisi
Andrea Scalisi
BNBruno Franco Novelletto
Bruno Franco Novelletto
MFMassimo Fusello
Massimo Fusello
RMRaffaella Michieli
Raffaella Michieli
MCMaurizio Cancian
Maurizio Cancian
Context: Both frailty and multimorbidity are strong predictors of clinical endpoints for older people. In Italy, the interventions targeting chronicity are mainly based on the treatment of diseases: sufficient epidemiological literature is available about these strategies. Less is known about the territorial distribution of the frailty status. Aims: To estimate the prevalence of frailty in older people (65+) and to evaluate the relationship between frailty and multimorbidity. Methods and material: A group of general practitioners working in Veneto (Italy) was enrolled on a voluntary basis. Older individuals were both community dwelling and institutionalized patients, that is, the older people normally followed by Italian general practitioners. A centrally randomized sample was extracted from the pool of physician-assisted elderly. Each doctor evaluated the frailty status through the CSHA Clinical Frailty Scale and the multimorbidity status through the Charlson score (Frailty = CSHA Clinical Frailty Scale’s score >4; serious multimorbidity = Charlson score ≥4). Prevalence and its confidence interval (CI) 95% were evaluated through the Agresti’s method for proportions. The relation between frailty and multimorbidity was studied through a logistic regression model adjusted for age and sex. Results: Fifty-three physicians were enrolled, whose population of elderly individuals (N = 82919) was highly representative of the population of Veneto. The prevalence of frailty in the randomized sample of 2407 older people was 23.18% (CI 95%: 21.53%–24.91%). Sex was shown to be a strong predictor of frailty (female status OR = 1.58 p < .0001) and multimorbidity was shown to be an independent predictor only for individuals <85 years of age. Conclusions: In Veneto, more than 20% of elderly people are frail. Physicians should pay close attention to frailty and multimorbidity because both are important prognostic factors toward clinical endpoints relevant to territorial care. The CSHA Clinical Frailty Scale (easy and quick) should become part of their professional routine.